Message from the CEO
FIMECS, Inc. is dedicated to Targeted Protein Degradation (TPD), developing novel therapeutics for targets previously considered undruggable. Our drug discovery platform, RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System), enables the rapid synthesis and evaluation of large numbers of degrader compounds, helping generate development candidates in short order. Through a phenotype-driven TPD screening approach, RaPPIDS makes it possible to identify the most suitable E3 ligase for each target protein. In the course of this work, we have also identified novel E3 ligase binders with distinctive expression profiles—an important strength that allows us to offer multiple options aimed at achieving both safety and therapeutic efficacy.
What turns this platform into a true competitive advantage is the FIMECS team itself. With deep expertise in drug discovery, our members are committed to advancing programs with both speed and quality in mind—without compromise.
We pursue research with integrity and take on challenges with relentless ambition. By leveraging our scientific differentiation, FIMECS will continue to build a globally competitive drug discovery company—delivering hope to patients and their families.
Chief Executive Officer